A Phase 2 interventional study of [18F]FAPI-74 PET/CT in Gastrointestinal Cancers, Cholangiocarcinoma and Gastric Cancer, sponsored by SOFIE. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by SOFIE · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 316 studies in Gastrointestinal Neoplasms with a site in United States — 83 open to participants now, 116 under way, 4 of them phase 3. Gastrointestinal Neoplasms · United States.
Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, this one is the 82nd largest by enrollment of the 245 interventional ones that give a count, is one of 25 that started in 2023, is one of 42 in phase 2, and was the 237th registered.
696 studies on the registry are indexed under Gastrointestinal Neoplasms; 210 are open to participants now.
Browse Gastrointestinal Neoplasms studies →83 of the 316 studies in Gastrointestinal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 18–99
Orlando Health, Inc. · Sites in United States
Ages 18–100
Northwestern University · Sites in United States
Ages 18+
BigHat Biosciences, Inc. · Sites in United States
Ages 18+
Genmab · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 160 Gastrointestinal Neoplasms studies recruiting now, 122 (76%) set no upper age limit and 18 (11%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
316 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 96 · Phase 2 82 · Phase 3 12 · Phase 4 4
First in 1995; this study’s year is marked. 25 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 74 across 495 interventional studies indexed under Gastrointestinal Neoplasms.
Median enrollment 60 across the 245 interventional studies, 165 across the 64 observational. Of the 182 that completed or were terminated, 68 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 316 have an industry lead sponsor. The 10 most frequent:
SOFIE is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
SOFIE has 1 study filed under Gastrointestinal Neoplasms — fewer than ten, so there is no comparison to draw.
40 of the studies in Gastrointestinal Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06511037University of California, IrvinePhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis | 2026-11-30 |
| NCT05318027Abramson Cancer Center at Penn MedicineChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy | 2026-12 |
| NCT06065371Henry Ford Health SystemSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 2026-12 |
| NCT06569693University of MiamiDyadic Sleep Study | 2026-12-01 |
| NCT06134687Baylor College of MedicineNovel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection | 2026-12-04 |
Add all 40 to your calendar (.ics) → With an account.
Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma, cholangiocarcinoma, gastric, pancreatic and colorectal cancer. The [18F]FAPI-74 PET scan will be acquired in patients with proven GI cancers after initial staging using institutional standard methods. The PET scan results will be compared to FAP immunohistochemistry (as the primary objective) and histopathology (as the secondary objective) of the biopsied or resected tissues.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive \[18F\]FAPI-74 intravenously followed by PET/CT 60 minutes (+/-10minutes) later
Drug: [18F]FAPI-74 PET/CT
Drug page: Fluorine F 18 FAPI-74
\[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.
Positive Predictive Value (PPV) of [18F]FAPI-74 PET Imaging Using Immunohistochemistry (IHC)
The positive or negative status according to \[18F\]FAPI-74 PET imaging was determined based on a prespecified cut-off value for each appropriate test as determined by the clinician. Positivity was evaluated using the following prespecified H-score thresholds: \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only. The primary efficacy endpoint was the positive predictive value of \[18F\]FAPI-74 PET imaging, defined as the proportion of PET-positive results that were confirmed positive by IHC. PPV was summarized using proportions along with two-sided 95% asymptotic normal confidence intervals.
Time frame: Day 1
Sensitivity of [18F]FAPI-74 PET Imaging to Detect FAP-Expressing Cells, Using IHC
Sensitivity was defined as the proportion of participants with IHC confirmed FAP-expressing cells who had a positive \[18F\]FAPI-74 PET result for the primary lesion. Sensitivity was calculated as A / (A + C), where A represents true positive findings and C represents false negative findings. Higher sensitivity indicates a greater ability of \[18F\]FAPI-74 PET to detect IHC confirmed FAP expression and a lower likelihood of false negative results, thereby reflecting the effectiveness of the imaging modality relative to the IHC reference standard. Sensitivity was presented overall for all IHC-positive results and separately using stricter IHC cut-off values categorized as: \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.
Time frame: Day 1
Specificity of [18F]FAPI-74 PET Imaging to Detect Absence of FAP-Expressing Cells, Using IHC as Truth Standard
Specificity was defined as the proportion of participants without IHC-confirmed FAP-expressing cells who had a negative \[18F\]FAPI-74 PET result for the primary lesion. Specificity was calculated by comparing positive and negative \[18F\]FAPI-74 PET findings with the corresponding IHC results, using a single readable PET image matched to its reference IHC assessment. Specificity was calculated as D / (B + D), where B represents false-positive findings and D represents true-negative findings. PET results were compared with the corresponding IHC reference assessment using a single readable PET image per participant. Specificity was evaluated overall using IHC negativity defined as \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.
Time frame: Day 1
PPV of [18F]FAPI-74 PET Images to Detect Cancer Cells Using Histopathology as Truth Standard
Positive Predictive Value (PPV) of \[18F\]FAPI-74 PET imaging in detecting presence of disease using histopathology as the truth standard. The PPV is defined as the probability that one is indeed positive for an outcome given that they test positive for the outcome and is calculated as: PPV = A/(A + B), where A represents true-positive findings and B represents false-positive findings (PET positive but histopathology negative). PPV was summarized using proportions along with two-sided 95% asymptotic normal confidence intervals.
Time frame: Day 1
Sensitivity of [18F]FAPI-74 PET Imaging to Detect Cancers Cells, Using Histopathology as Truth Standard
Sensitivity was defined as the proportion of participants with histopathology-confirmed cancers cells who had a positive \[18F\]FAPI-74 PET result for the primary lesion. Sensitivity was calculated by comparing positive and negative \[18F\]FAPI-74 PET findings with the corresponding histopathology results, using a single readable PET image matched to its reference histopathology assessment. Sensitivity was calculated as A / (A + C), where A represents true-positive findings and C represents false-negative findings. Sensitivity was summarized using proportions along with two-sided 95% asymptotic normal confidence intervals.
Time frame: Day 1
Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) is any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the trial intervention. A TEAE is defined as any untoward medical occurrence that begins or worsens in intensity or frequency after the initiation of a treatment (e.g., drug, device, or procedure) in a clinical study. A serious TEAE is defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization.
Time frame: From study intervention administration (Day 1) to 72 hours post-injection
This was a Phase 2, prospective, non-randomized, open-label, multicenter clinical trial that evaluated the efficacy of administering \[18F\]FAPI-74 to detect fibroblast activation protein (FAP) expressing cells in participants diagnosed with gastrointestinal (GI) cancers.
| Milestone | [18F]FAPI-74 PET/CT |
|---|---|
| Started | 112 |
| Completed | 95 |
| Not completed | 17 |
| Withdrew: Death | 1 |
| Withdrew: Protocol deviation | 4 |
| Withdrew: Withdrawal by participant | 5 |
| Withdrew: Other (unspecified) | 7 |
The positive or negative status according to \[18F\]FAPI-74 PET imaging was determined based on a prespecified cut-off value for each appropriate test as determined by the clinician. Positivity was evaluated using the following prespecified H-score thresholds: \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only. The primary efficacy endpoint was the positive predictive value of \[18F\]FAPI-74 PET imaging, defined as the proportion of PET-positive results that were confirmed positive by IHC. PPV was summarized using proportions along with two-sided 95% asymptotic normal confidence intervals.
| Proportion of participants | [18F]FAPI-74 PET/CT |
|---|---|
| IHC Cutoff: >50 | 1.0000 (1.000 to 1.000) |
| IHC Cutoff: >100 | 0.7500 (0.632 to 0.868) |
| IHC Cutoff: >200 | 0.2885 (0.165 to 0.412) |
Sensitivity was defined as the proportion of participants with IHC confirmed FAP-expressing cells who had a positive \[18F\]FAPI-74 PET result for the primary lesion. Sensitivity was calculated as A / (A + C), where A represents true positive findings and C represents false negative findings. Higher sensitivity indicates a greater ability of \[18F\]FAPI-74 PET to detect IHC confirmed FAP expression and a lower likelihood of false negative results, thereby reflecting the effectiveness of the imaging modality relative to the IHC reference standard. Sensitivity was presented overall for all IHC-positive results and separately using stricter IHC cut-off values categorized as: \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.
| Proportion of participants | [18F]FAPI-74 PET/CT |
|---|---|
| IHC Cutoff: >50 | 0.8966 (0.818 to 0.975) |
| IHC Cutoff: >100 | 0.8667 (0.767 to 0.966) |
| IHC Cutoff: >200 | 0.8824 (0.729 to 1.000) |
Specificity was defined as the proportion of participants without IHC-confirmed FAP-expressing cells who had a negative \[18F\]FAPI-74 PET result for the primary lesion. Specificity was calculated by comparing positive and negative \[18F\]FAPI-74 PET findings with the corresponding IHC results, using a single readable PET image matched to its reference IHC assessment. Specificity was calculated as D / (B + D), where B represents false-positive findings and D represents true-negative findings. PET results were compared with the corresponding IHC reference assessment using a single readable PET image per participant. Specificity was evaluated overall using IHC negativity defined as \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.
| Proportion of participants | [18F]FAPI-74 PET/CT |
|---|---|
| IHC Cutoff: >50 | 1.0000 (1.000 to 1.000) |
| IHC Cutoff: >100 | 0.1333 (0.000 to 0.305) |
| IHC Cutoff: >200 | 0.1395 (0.036 to 0.243) |
Positive Predictive Value (PPV) of \[18F\]FAPI-74 PET imaging in detecting presence of disease using histopathology as the truth standard. The PPV is defined as the probability that one is indeed positive for an outcome given that they test positive for the outcome and is calculated as: PPV = A/(A + B), where A represents true-positive findings and B represents false-positive findings (PET positive but histopathology negative). PPV was summarized using proportions along with two-sided 95% asymptotic normal confidence intervals.
| Proportion of participants | [18F]FAPI-74 PET/CT |
|---|---|
| PPV of [18F]FAPI-74 PET Images to Detect Cancer Cells Using Histopathology as Truth Standard | 0.9423 (0.841 to 0.988) |
Sensitivity was defined as the proportion of participants with histopathology-confirmed cancers cells who had a positive \[18F\]FAPI-74 PET result for the primary lesion. Sensitivity was calculated by comparing positive and negative \[18F\]FAPI-74 PET findings with the corresponding histopathology results, using a single readable PET image matched to its reference histopathology assessment. Sensitivity was calculated as A / (A + C), where A represents true-positive findings and C represents false-negative findings. Sensitivity was summarized using proportions along with two-sided 95% asymptotic normal confidence intervals.
| Proportion of participants | [18F]FAPI-74 PET/CT |
|---|---|
| Sensitivity of [18F]FAPI-74 PET Imaging to Detect Cancers Cells, Using Histopathology as Truth Standard | 0.9074 (0.797 to 0.969) |
An adverse event (AE) is any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the trial intervention. A TEAE is defined as any untoward medical occurrence that begins or worsens in intensity or frequency after the initiation of a treatment (e.g., drug, device, or procedure) in a clinical study. A serious TEAE is defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization.
| Participants | [18F]FAPI-74 PET/CT |
|---|---|
| Any TEAE | 6 |
| Any Serious TEAE | 2 |
Collected over From study intervention administration (Day 1) to 72 hours post-injection. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| [18F]FAPI-74 PET/CT | 1/109 (0.9%) | 2/109 (1.8%) | 6/109 (5.5%) |
| Event | [18F]FAPI-74 PET/CT |
|---|---|
| Intestinal perforationGastrointestinal disorders | 1/109 |
| PainGeneral disorders | 1/109 |
| Pneumonia aspirationInfections and infestations | 1/109 |
| Liver function test increasedInvestigations | 1/109 |
| Event | [18F]FAPI-74 PET/CT |
|---|---|
| NauseaGastrointestinal disorders | 2/109 |
| Blood bilirubin increasedInvestigations | 1/109 |
| Hepatic enzyme increasedInvestigations | 1/109 |
| Liver function test increasedInvestigations | 1/109 |
| Lymphocyte count decreasedInvestigations | 1/109 |
| HeadacheNervous system disorders | 1/109 |
Safety Analysis Set (SAS) comprises of all participants who received any amount of \[18F\]FAPI-74.
| Age, Continuous(years) | [18F]FAPI-74 PET/CT |
|---|---|
| Mean | 53.85 ± 10.82 |
| Sex: Female, Male(Participants) | [18F]FAPI-74 PET/CT |
|---|---|
| Female | 47 |
| Male | 62 |
| Ethnicity (NIH/OMB)(Participants) | [18F]FAPI-74 PET/CT |
|---|---|
| Hispanic or Latino | 8 |
| Not Hispanic or Latino | 95 |
| Unknown or Not Reported | 6 |
| Race/Ethnicity, Customized(Participants) | [18F]FAPI-74 PET/CT |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 16 |
| Black or African American | 8 |
| Native Hawaiian or Other Pacific Islander | 0 |
| White | 66 |
| Not Reported | 0 |
| Unknown | 10 |
| Multiracial | 0 |
| Other | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Apr 2023 to primary completion in Jun 2025, 26 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 55 phase 2 interventional studies under Gastrointestinal Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's 26 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluorine F 18 FAPI-74
SOFIE